Skip to main content

CD19/CD22-CAR-transduced T cells

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  • RegistryNCT05442515
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionB-Non Hodgkin Lymphoma
  • SponsorNational Cancer Institute (NCI)
How CD19/CD22-CAR-transduced T cells worksNCT054425151 min

What the film says

Read the transcript

Acute lymphoblastic leukemia is the most common childhood cancer, and nine in ten are cured. When it comes back, the odds fall below half.

CAR T cells aimed at a marker called CD19 rescued many of those children. But leukemia learns: some cells drop CD19 and slip away. Cells aimed at a second marker, CD22, get dodged the same way.

The idea: one T cell that watches both doors at once.

A child's own T cells receive one gene that builds both receptors. The National Cancer Institute's earlier two-target design was safe, but the cells faded quickly. This version is rebuilt to last.

Sara Silbert leads it at the NIH Clinical Center, for ages three to thirty-nine. Safety first. Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

CD19/CD22-CAR-transduced T cells on D0 after lymphodepleting preparative regimen

Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion.

Background: * Despite improvements in therapy, acute lymphoblastic leukemia (ALL) contributes to significant morbidity and mortality for children and young adults with cancer. CD19-CAR and CD22-CAR therapy have proven highly effective in inducing remission in patients with relapsed/refractory disease. * Immune escape has been observed by several groups following CD19-CAR and CD22- CAR therapy for B-ALL.

The study

How the trial runs.

Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses. Objective: To test chimeric antigen receptor (CAR) therapy.

CARs are genetically modified cells created from each patient s own blood cells. his trial will use a new type of CAR T-cell that is targeting both CD19 and CD22 at the same time. CD19 and CD22 are proteins found on the surface of most types of ALL. Eligibility: People aged 3 to 39 with ALL or related B-cell lymphoma that has not been cured by standard therapy. Design: Participants will be screened.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Have pathology confirmed B cell ALL (not isolated to the testis or CNS), CML with ALL transformation, or high-grade lymphoma (e.g., Burkitt's lymphoma, B-lymphoblastic lymphoma, diffuse large B-cell lymphoma, inclusive of low-grade lymphoma that has transformed to high grade disease); and
  • Have relapsed or been refractory after at least one standard chemotherapy regimen and at least one salvage treatment. Participants with Philadelphia chromosome + ALL must have failed prior tyrosine kinase inhibitor; and
  • Be ineligible for allogeneic stem cell transplant (SCT), have refused SCT, or have recurred after SCT; and
  • Be unable to access (in a timely manner), ineligible for, or have relapsed/failed after or not responded to a commercially available CD19 CAR T-cell construct; and
  • Have evidence of at least minimal residual disease or PET-avid disease (lymphoma) at the time of enrollment.
  • CD22/CD19 expression

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.